Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00567814 · ClinicalTrials.gov registry record · NA

A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction

A NA study of Cocaine Dependence and Cocaine Addiction, sponsored by Embera NeuroTherapeutics.

Completed
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT00567814: Completed NA study of Cocaine Dependence and Cocaine Addiction, sponsored by Embera NeuroTherapeutics.

NCT00567814 is a NA study of Cocaine Dependence and Cocaine Addiction that has completed, run by Embera NeuroTherapeutics. The registered enrollment target is 45 participants, below the 297-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00567814, a NA study of Cocaine Dependence and Cocaine Addiction, has completed, sponsored by Embera NeuroTherapeutics.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

Subjects will be randomly assigned to receive either one of the two potential dose combinations of the study medications or placebo over 6 weeks. The study will include twice weekly visits to the research clinic for laboratory studies, safety assessments and urine drug screens. Subjects will also be questioned regarding drug craving and mood symptoms.

Interventions

  • DRUG Placebo
  • DRUG Metyrapone
  • DRUG Oxazepam

Study Locations (1)

Louisiana

  • Department of Psychiatry, Psychopharmacology Research Clinic - Shreveport

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2007-12
Est. Completion 2008-11
Phase NA
Embera NeuroTherapeutics

6 total trials

What the finished NCT00567814 record still lists

NCT00567814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 297-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Cocaine Dependence appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00567814 reports a single indexed study location in Louisiana.

Frequently Asked Questions

What is clinical trial NCT00567814 about?

NCT00567814 is a clinical study titled "A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction". Subjects will be randomly assigned to receive either one of the two potential dose combinations of the study medications or placebo over 6 weeks. The study will include twice weekly visits to the research clinic for laboratory studies, safety assessments and urine drug screens. Subjects will also be...

What is the current status of trial NCT00567814?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2007-12. Estimated completion is 2008-11.

What conditions does trial NCT00567814 study?

This clinical trial studies the following conditions: Cocaine Dependence, Cocaine Addiction.

What interventions are being tested in trial NCT00567814?

The interventions under investigation include: Placebo (DRUG), Metyrapone (DRUG), Oxazepam (DRUG).

Who is sponsoring clinical trial NCT00567814?

This trial is sponsored by Embera NeuroTherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00567814 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine Dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00567814's enrollment target sits among peer trials

45 25th of 38 higher than 13 of 38 other Cocaine Dependence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cocaine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00567814, the US trial registry maintained by the National Library of Medicine. NCT00567814 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.